{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:58:38Z","timestamp":1764053918244},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018"],"award-info":[{"award-number":["BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018","BT\/NNT\/28\/SP18830\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s10038-024-01267-0","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:25:10Z","timestamp":1719883510000},"page":"467-474","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating druggable kinases for targeted therapy in retinoblastoma"],"prefix":"10.1038","volume":"69","author":[{"given":"Kumar","family":"Jeyaprakash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manojkumar","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Santhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerappan","family":"Muthukkaruppan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharanidharan","family":"Devarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayyasamy","family":"Vanniarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"1267_CR1","doi-asserted-by":"publisher","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","volume":"1","author":"H Dimaras","year":"2015","unstructured":"Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. Nat Rev Dis Prim. 2015;1:15021.","journal-title":"Nat Rev Dis Prim"},{"key":"1267_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature13813","volume":"514","author":"XL Xu","year":"2014","unstructured":"Xu XL, Singh HP, Wang L, Qi D-L, Poulos BK, Abramson DH, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature. 2014;514:385\u201388.","journal-title":"Nature"},{"key":"1267_CR3","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","volume":"68","author":"D Ancona-Lezama","year":"2020","unstructured":"Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68:2356\u201365.","journal-title":"Indian J Ophthalmol"},{"key":"1267_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11940-007-0015-4","volume":"9","author":"C Rodriguez-Galindo","year":"2007","unstructured":"Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol. 2007;9:294\u2013307.","journal-title":"Curr Treat Options Neurol"},{"key":"1267_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48.","journal-title":"Mol Cancer"},{"key":"1267_CR6","doi-asserted-by":"crossref","unstructured":"Shapiro P, Martinez R, Defnet A. Introduction to kinases, cellular signaling, and kinase inhibitors. In: Shapiro P, editor. Next generation kinase inhibitors: moving beyond the ATP binding\/catalytic sites. Cham: Springer International Publishing; 2020. p. 1-12.","DOI":"10.1007\/978-3-030-48283-1_1"},{"key":"1267_CR7","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/JCI76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125:1780\u20139.","journal-title":"J Clin Invest"},{"key":"1267_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C. Targeted cancer therapy. Nature. 2004;432:294\u20137.","journal-title":"Nature"},{"key":"1267_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP. et al. Long-term outcomes imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"1267_CR10","doi-asserted-by":"publisher","first-page":"106552","DOI":"10.1016\/j.phrs.2022.106552","volume":"187","author":"R Roskoski Jr","year":"2023","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552.","journal-title":"Pharmacol Res"},{"key":"1267_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820\u20133.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1267_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1146\/annurev-pathol-012414-040259","volume":"10","author":"CA Benavente","year":"2015","unstructured":"Benavente CA, Dyer MA. Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 2015;10:547\u201362.","journal-title":"Annu Rev Pathol"},{"key":"1267_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/156800907782418266","volume":"7","author":"N Laurie","year":"2007","unstructured":"Laurie N, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689\u201395.","journal-title":"Curr Cancer Drug Targets"},{"key":"1267_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature10733","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329\u201334.","journal-title":"Nature"},{"key":"1267_CR15","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.tranon.2020.100971","volume":"14","author":"J Sujjitjoon","year":"2021","unstructured":"Sujjitjoon J, Sayour E, Tsao ST, Uiprasertkul M, Sanpakit K, Buaboonnam J, et al. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction. Transl Oncol. 2021;14:100971.","journal-title":"Transl Oncol"},{"key":"1267_CR16","doi-asserted-by":"publisher","first-page":"822330","DOI":"10.3389\/fonc.2022.822330","volume":"12","author":"P Schaiquevich","year":"2022","unstructured":"Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of retinoblastoma: what is the latest and what is the future. Front Oncol. 2022;12:822330","journal-title":"Front Oncol"},{"key":"1267_CR17","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids Res. 1988;16:1215.","journal-title":"Nucleic acids Res"},{"key":"1267_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1340-8","volume":"15","author":"B Devarajan","year":"2015","unstructured":"Devarajan B, Prakash L, Kannan TR, Abraham AA, Kim U, Muthukkaruppan V, et al. Targeted next generation sequencing of RB1 gene for the molecular diagnosis of retinoblastoma. BMC Cancer. 2015;15:320.","journal-title":"BMC Cancer"},{"key":"1267_CR19","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1093\/hmg\/ddu733","volume":"24","author":"C Dong","year":"2015","unstructured":"Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24:2125\u201337.","journal-title":"Hum Mol Genet"},{"key":"1267_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/pro.3746","volume":"29","author":"RA Laskowski","year":"2020","unstructured":"Laskowski RA, Stephenson JD, Sillitoe I, Orengo CA, Thornton JM. VarSite: disease variants and protein structure. Protein Sci. 2020;29:111\u201319.","journal-title":"Protein Sci"},{"key":"1267_CR21","doi-asserted-by":"publisher","first-page":"5.6.1","DOI":"10.1002\/cpbi.3","volume":"54","author":"B Webb","year":"2016","unstructured":"Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr Protoc Bioinform. 2016;54:5.6.1\u20135.6.37.","journal-title":"Curr Protoc Bioinform"},{"key":"1267_CR22","doi-asserted-by":"publisher","first-page":"W350","DOI":"10.1093\/nar\/gky300","volume":"46","author":"CH Rodrigues","year":"2018","unstructured":"Rodrigues CH, Pires DE, Ascher DB. DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic acids Res. 2018;46:W350\u2013W55.","journal-title":"Nucleic acids Res"},{"key":"1267_CR23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1593\/neo.111252","volume":"13","author":"RJ Lonigro","year":"2011","unstructured":"Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia. 2011;13:1019\u201325.","journal-title":"Neoplasia"},{"key":"1267_CR24","unstructured":"Oliveira C, Wolf T. CNVPanelizer: reliable CNV detection in targeted sequencing applications. R package version 1.18.0. 2019. https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/CNVPanelizer.html."},{"key":"1267_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/1568009620666200504112711","volume":"20","author":"S Balaji","year":"2020","unstructured":"Balaji S, Santhi R, Kim U, Muthukkaruppan V, Priya CG, Vanniarajan A. Cancer stem cells with overexpression of neuronal markers enhance chemoresistance and invasion in retinoblastoma. Curr Cancer Drug Targets. 2020;20:710\u201319.","journal-title":"Curr Cancer Drug Targets"},{"key":"1267_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep25264","volume":"6","author":"IE Kooi","year":"2016","unstructured":"Kooi IE, Mol BM, Massink MP, Ameziane N, Meijers-Heijboer H, Dommering CJ, et al. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. Sci Rep. 2016;6:25264.","journal-title":"Sci Rep"},{"key":"1267_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ophtha.2019.12.005","volume":"127","author":"AR Afshar","year":"2020","unstructured":"Afshar AR, Pekmezci M, Bloomer MM, Cadenas NJ, Stevers M, Banerjee A, et al. Next-generation sequencing of retinoblastoma identifies pathogenic alterations beyond RB1 inactivation that correlate with aggressive histopathologic features. Ophthalmology. 2020;127:804\u201313.","journal-title":"Ophthalmology"},{"key":"1267_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/cancers13010149","volume":"13","author":"JH Francis","year":"2021","unstructured":"Francis JH, Richards AL, Mandelker DL, Berger MF, Walsh MF, Dunkel IJ, et al. Molecular changes in retinoblastoma beyond RB1: findings from next-generation sequencing. Cancers. 2021;13:149.","journal-title":"Cancers"},{"key":"1267_CR29","doi-asserted-by":"publisher","first-page":"108753","DOI":"10.1016\/j.exer.2021.108753","volume":"211","author":"V Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a V, Evangelista AC, Matta BP, Moreira M\u00c2M, Faria P, Lucena E, et al. Molecular alterations in retinoblastoma beyond RB1. Exp Eye Res. 2021;211:108753.","journal-title":"Exp Eye Res"},{"key":"1267_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.","journal-title":"Mol Cancer"},{"key":"1267_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/emmm.201101131","volume":"4","author":"NA Saunders","year":"2012","unstructured":"Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012;4:675\u201384.","journal-title":"EMBO Mol Med"},{"key":"1267_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/gcc.20383","volume":"46","author":"E Bowles","year":"2007","unstructured":"Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosom Cancer. 2007;46:118\u201329.","journal-title":"Genes Chromosom Cancer"},{"key":"1267_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/gcc.20457","volume":"46","author":"TW Corson","year":"2007","unstructured":"Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosom Cancer. 2007;46:617\u201334.","journal-title":"Genes Chromosom Cancer"},{"key":"1267_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ceo.12132","volume":"42","author":"BL Th\u00e9riault","year":"2014","unstructured":"Th\u00e9riault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014;42:33\u201352.","journal-title":"Clin Exp Ophthalmol"},{"key":"1267_CR35","unstructured":"Thangavel R, Bhaskaran S, Demirei H. Chemofailure and chemoresistance in retinoblastoma. IP Int J Ocul Oncol Oculoplasty. 2017;3:2\u20137."},{"key":"1267_CR36","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115\u201332.","journal-title":"Theranostics"},{"key":"1267_CR37","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1038\/onc.2013.48","volume":"32","author":"PE L\u00f8nning","year":"2013","unstructured":"L\u00f8nning PE, Knappskog S. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 2013;32:5315\u201330.","journal-title":"Oncogene"},{"key":"1267_CR38","doi-asserted-by":"publisher","unstructured":"Xu L, Kim ME, Polski A, Prabakar RK, Shen L, Peng C-C, et al. Establishing the clinical utility of ctDNA analysis for diagnosis, prognosis, and treatment monitoring of retinoblastoma: the aqueous humor liquid biopsy. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13061282.","DOI":"10.3390\/cancers13061282"},{"key":"1267_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/tvst.9.10.30","volume":"9","author":"A Polski","year":"2020","unstructured":"Polski A, Xu L, Prabakar RK, Kim JW, Shah R, Jubran R, et al. Cell-free DNA tumor fraction in the aqueous humor is associated with therapeutic response in retinoblastoma patients. Transl Vis Sci Technol. 2020;9:30\u20130.","journal-title":"Transl Vis Sci Technol"},{"key":"1267_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/cancers13040673","volume":"13","author":"R Aschero","year":"2021","unstructured":"Aschero R, Francis JH, Ganiewich D, Gomez-Gonzalez S, Sampor C, Zugbi S, et al. Recurrent somatic chromosomal abnormalities in relapsed extraocular retinoblastoma. Cancers. 2021;13:673.","journal-title":"Cancers"},{"key":"1267_CR41","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15:1781\u201391.","journal-title":"Mol Cancer Ther"},{"key":"1267_CR42","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc060020","volume":"354","author":"F Cappuzzo","year":"2006","unstructured":"Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006;354:2619\u201321.","journal-title":"N Engl J Med"},{"key":"1267_CR43","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/cam4.268","volume":"3","author":"M Fernanda Amary","year":"2014","unstructured":"Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med. 2014;3:980\u20137.","journal-title":"Cancer Med"},{"key":"1267_CR44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","volume":"78","author":"MY Teo","year":"2020","unstructured":"Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, et al. Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma. Eur Urol. 2020;78:907\u201315.","journal-title":"Eur Urol"},{"key":"1267_CR45","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1002\/cncr.33071","volume":"126","author":"V McPherson","year":"2020","unstructured":"McPherson V, Reardon B, Bhayankara A, Scott SN, Boyd ME, Garcia-Grossman IR, et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. 2020;126:4532\u201344.","journal-title":"Cancer"},{"key":"1267_CR46","doi-asserted-by":"publisher","first-page":"e20053","DOI":"10.1097\/MD.0000000000020053","volume":"99","author":"L Sun","year":"2020","unstructured":"Sun L, Yang M, Zhang X, Li H, Wu L, Zhang Y, et al. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: a case report. Medicine. 2020;99:e20053.","journal-title":"Medicine"}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s10038-024-01267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-024-01267-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-024-01267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T19:02:55Z","timestamp":1724526175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s10038-024-01267-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1038\/s10038-024-01267-0","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"type":"print","value":"1434-5161"},{"type":"electronic","value":"1435-232X"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval for this study was granted by the Institutional Ethics Review Board at the Aravind Medical Research Foundation, India (Ethical approval no: IRB2016017BAS). The research was conducted in accordance with the principles outlined in the 1964 Declaration of Helsinki and its subsequent revisions, or equivalent ethical guidelines. Written consent was obtained from the parents of retinoblastoma children who participated in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}